How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Recombinant antibody for easy detection of mucolipidosis type II and III and selective purification of proteins with mannose 6-phosphate residues for ERT

Organization name

Ascenion GmbH



Currently, the diagnosis of ML II and III can only be carried out in a few specialized laboratories throughout the world due to a complex procedure. In addition, purification of enzymes for ERT requires expensive chromatographic procedures which do not discriminate between therapeutically active and inactive forms, i.e. with or without Man6P modification.


The inventors have generated a recombinant antibody (M6P-1) specifically binding to Man6P. They have shown on a laboratory scale that it allows

  • easy diagnosis of ML II and III by western blots
  • selective purification in a one-step procedure of recombinant high-affinity uptake forms of lysosomal enzymes on affinity media (see figure)
  • histological staining of lysosomes.

The protein expresses well in a prokaryotic host, can be purified to homogeneity, is stable over several months at 4 °C and can be immobilized on affinity media without loss of activity.

Commercial Opportunity

The technology is offered for co-development of a diagnostic kit and an optimized cost-efficient purification procedure or for in-licensing.

Patent Situation

A European patent application has been filed in August 2008 and a PCT-application in August 2009.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries